Consensus Faron Pharmaceuticals Oy

Equities

FARN

FI4000153309

Market Closed - London S.E. Other stock markets 11:35:05 2024-05-17 am EDT			5-day change	1st Jan Change
250 ^GBX	0.00%		+26.58%	-18.03%

May. 03	Kelso raises stake in NCC; Transense joins project	AN
Apr. 30	Faron Pharmaceuticals Ltd. Announces Appointment of Dr. Juho Jalkanen as Director	CI

Evolution of the average Target Price on Faron Pharmaceuticals Oy

Price target over the last 5 years

History of analyst recommendation changes

a5cafbc24bf95c29194.smQ0fg7tT0p-h80pZwqrvxsvUfaYxvcrlDPyqNe7LX0.4RUCGU-Ffxgz0IZQCzyZ80FsGbSsnINI0mXA26WIHQzEHFoydqQjDDn09Q~1f87e379c97eac4465b084c14cf5a355

Analyst Recommendations on Faron Pharmaceuticals Oy

Faron Pharmaceuticals Reports 100% Response Rate in Phase 1 Trial of Myeloid Leukemia Combo Drug	Jan. 25	MT
Faron Pharmaceuticals' Bexmarilimab shows 50% remission rate	23-10-11	AN
Faron Halts Investigational COVID-19 Therapy Trial Due to Low Infection, Hospitalization Rates	22-04-05	MT
Faron Closes HIBISCUS Trial Due to Low COVID-19 Infection and Hospitalization Rates in the US and Reverts Resources to the Development of Bexmarilimab	22-04-05	CI

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.922 EUR

Average target price

11.6 EUR

Spread / Average Target

+297.16%

High Price Target

11.6 EUR

Spread / Highest target

+297.16%

Low Price Target

11.6 EUR

Spread / Lowest Target

+297.16%

Consensus detail

Consensus revision (last 18 months)

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar